Omega-3 compositions, dosage forms, and methods of use
Omega-3 compositions, dosage forms, and methods of use are disclosed herein. The omega-3 compositions and dosage forms disclosed herein may comprise DHA and EPA at a ratio of about 5:2. The omega-3 compositions and dosage forms disclosed herein may comprise re-esterified triglycerides. Methods of treatment using the compositions and dosage forms are also disclosed.
1. A method of reducing the resting heart rate of a
subject, the method comprising:
administering a therapeutically-effective amount of a processed marine oil composition comprising fatty acid esters, wherein the fatty acid esters comprise esters of omega-3 polyunsaturated fatty acids (PUFAs), including re-esterified esters of 4Z,7Z, 10Z,13Z,16Z,19Z-docosahexaenoic acid (DHA) and re-esterified esters of 5Z,8Z,11Z, 14Z,17Z-eicosapentaenoic acid (EPA), wherein a ratio of re-esterified esters of DHA to re-esterified esters of EPA is about 2.5:1 to about 4:1, wherein at least about 50% of the fatty acid esters are re-esterified triglycerides (rTGs).
2. The method of claim 1 , wherein a dose of DHA is at least about 1800 mg/day.
3. The method of claim 2 , wherein the dose of DHA is about 1800 mg/day to about 2400 mg/day.
4. The method of claim 2 , wherein a dose of EPA is about 700 mg/day to about 1000 mg/day.
5. The method of claim 2 , wherein the dose of DHA is about 900 mg to about 1200 mg, twice a day, and the dose of EPA is about 350 mg to about 500 mg, twice a day.
6. The method of claim 1 , wherein about 55% to about 70% of the fatty acid esters are re-esterified triglycerides (rTGs).
7. The method of claim 1 , wherein about 25% to about 45% of the fatty acid esters are re-esterified diglycerides (rDGs).
8. The method of claim 1 , wherein about 0 wt % to about 5 wt % of the fatty acid-esters are re-esterified monoglycerides (rMGs).
9. The method of claim 1 , wherein about 5 wt % or less of the fatty acid esters are in the form of ethyl esters.
10. The method of claim 1 , wherein at least about 60 wt % of the fatty acid esters are esters of PUFAs.
11. The method of claim 1 , wherein at least about 15 wt % of the marine oil is derived from cephalopod oil.
12. A method of increasing high-density lipoprotein cholesterol (HDL-c) in a subject, the method comprising:
administering a therapeutically-effective amount of a processed marine oil composition comprising fatty acid esters, wherein the fatty acid esters comprise esters of omega-3 polyunsaturated fatty acids (PUFAs), including at least about 450 mg of re-esterified esters of 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid (DHA) and at least about 150 mg of re-esterified esters of 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic acid (EPA), wherein at least about 50% of the fatty acid esters are re-esterified triglycerides (rTGs).
13. The method of claim 12 , wherein the ratio of re-esterified esters of DHA to EPA is about 5:2.
14. The method of claim 12 , wherein at least about 55% of the fatty acid esters are re-esterified triglycerides (rTGs).
15. The method of claim 12 , wherein about 0 wt % to about 35 wt % of the fatty acid esters are esters of mono-unsaturated fatty acids.
16. The method of claim 12 , wherein about 0 wt % to about 5 wt % of the fatty acid esters are esters of saturated fatty acids.
17. The method of claim 12 , wherein at least about 50 wt % of the fatty acid esters are either re-esterified esters of DHA or re-esterified esters of EPA.
18. The method of claim 12 , wherein at least about 80% of the PUFAs are DHA and EPA.
19. A method of reducing triglycerides in a subject's blood, the method comprising:
administering a therapeutically-effective amount of a processed marine oil composition comprising fatty acid esters, wherein the fatty acid esters comprise esters of omega-3 polyunsaturated fatty acids (PUFAs), including re-esterified esters of 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid (DHA) and re-esterified esters of 5Z,8Z,11Z, 14Z,17Z-eicosapentaenoic acid (EPA), wherein a ratio of re-esterified esters of DHA to re-esterified esters of EPA is about 2.5:1 to about 4:1, wherein at least about 50% of the fatty acid esters are re-esterified triglycerides (rTGs).